Rupali Avasare, MD
Nephrology · Portland, ORNPI 1265676324
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,225 of the $15,955 with a category attached, or 95.4%. Boehringer Ingelheim accounts for 99.4% of it on its own, with 1 other manufacturer making up the rest. Among nephrology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $1772.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$16K
- Travere Therapeutics, Inc.$88
Across 6 payments — averaging $19,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$61K
- Calliditas Therapeutics US Inc.$40K
- Alnylam Pharmaceuticals Inc.$13K
What the payments were for
- Consulting fees$15,22595%
- Travel & lodging$4343%
- Food & beverage$2962%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $15,866 |
| Travere Therapeutics, Inc. | 1 | $88 |
How this compares
$15,955 in reported general payments places this provider in the 90th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcium Acetate | 16 | $1,174 |
| Sevelamer Carbonate | 11 | $989 |
| Doxazosin Mesylate | 14 | $786 |
| Losartan Potassium | 48 | $581 |
| Carvedilol | 34 | $543 |
| Atorvastatin Calcium | 18 | $401 |
| Chlorthalidone | 19 | $392 |
| Torsemide | 19 | $256 |
| Calcitriol | 18 | $255 |
| Nifedipine ErNifedipine | 11 | $216 |
| Amlodipine Besylate | 35 | $207 |
| Allopurinol | 17 | $200 |
| Lisinopril | 19 | $178 |
| Prednisone | 20 | $130 |
| Spironolactone | 13 | $93 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Portland
- Robert ProvenzanoPortland$45K
- Nayan AroraPortland$23K
- David EllisonPortland$12K
- Shehzad RehmanPortland$10K
- Arthur GreenbergPortland$7K
- Suzanne WatnickPortland$2K
- Hem DeodharPortland$1K
- Julia TankPortland$1K
- Chun Khai ChongPortland$956
- Maria Theresa de JesusPortland$857
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.